Another study takes on the unintentional unwanted effects of Novo Nordisk'S Semaglutid -The energetic ingredient in Blockbuster -Weight loss -Ticament Wegunaler and Diabetes -Treatment Ozempic.
But this time, The study Removes the danger of a hair loss.
To be clear, the link from Semaglutid with hair loss will not be recent. Clinical studies by Novo Nordisk have shown A better risk of hair loss In patients who earn Semaglutid in comparison with those that take a placebo.
Wegovy and Ozempic are a part of a category of popular medication called GLP-1 and imitate a hormone within the intestine to suppress the appetite and regulate the blood sugar. These drugs are known for his or her gastrointestinal unwanted effects similar to nausea and vomiting and were also faced after an increased examination Stomach paralysis And suicide thoughts during taking.
In an evidence, Novo Nordisk said that it was still the profit risk profile of our GLP 1 medication in the event that they are utilized in accordance with their indications and product identification “.
The new study carried out by researchers at the University of British Columbia and has not yet been submitted to check the peer shows that Semaglutid is associated with hair loss compared to users of an older weight loss pills called Contrave or BUPROPION NALTREXON.
The researchers examined data from 16 million patients from 2006 to 2020 and Identified 1,926 Semaglutid users and 1,348 Contrave user. People with a diagnosis of diabetes or antihyperglycaemia – medication with lower blood sugar levels – were excluded.
The incidence rates of hair loss were higher for semaglutid users than with contravic users. Overall, patients who revenue Semaglutid had a higher risk of hair loss compared to patients who competed.
The researchers also found that women who took Semaglutid had more than the two -time risk of hair loss compared to women in the contravic group. But Mohit Sodhi, one of the authors, told CNBC that “most of our data were driven by women”, so that they cannot compare men in the study.
Among those who took Semaglutid, there were 22 cases of hair loss in women and only one case among men. Future studies with larger sampling sizes of patients are required to determine whether there is a difference between men and women, says Sodhi.
The researchers did not follow the patient if they stop Semaglutid or criminals. It is therefore unclear whether the risk of a hair loss decreases according to Sodhi. Further investigations are required in this area, he said.
Why could SEMAGLUTID cause a higher risk of hair loss?
One factor could be the physiological stress that can cause rapid weight loss, which, according to Sodhi, can lead to the “disturbance of the natural hair cycle”. He said that could be an outstanding effect of the Semaglutide because it is known that it decreases faster than contrave.
The ability of Semaglutid to suppress appetite also leads to patients use less food, which may cause nutrient deficiencies, including protein, added Sodhi. It was shown that protein defects are associated with hair loss, he noticed.
So that said that patients at Semaglutid could also lose nutrients by vomiting. Some health experts also take on the hypothesis that Semaglutid can lead to hormonal shifts that can increase the risk of a common form of hair loss called androgenic alopecia, he added.
In particular, people and especially women, when considering using Semaglutid exclusively for weight loss, would like to communicate the researchers in the study. However, people with diabetes or pathological obesity can weigh up their risks and benefit differently and may be more willing to accept hair loss as a potential risk, the researchers added.
One of the authors of the study, Dr. Mahyar Etminan has previously consulted with legal disputes in connection with Ozempic.
Feel free to send Annika tips, suggestions, ideas and data Annikakim.constantino@nbcuni.com.
The latest in the healthcare system Tech: Dexcom receives warning letters from the FDA and appoints a new board member
Dexcom Received a warning letter from the US Food and Drug Administration last week after the agency inspected the company's production facilities in San Diego, California, and Mesa, Arizona.
The FDA observed “non -conformities” with the quality management system and the manufacturing processes of Dexcom, so A Friday company submission With the US Securities and Exchange Commission. The agency also found that the company's reaction to the list of observations that were formally referred to as form 483 is not sufficient.
“The company takes the matters identified within the warning letter seriously, has already submitted several answers to form 483 and is within the strategy of preparing a written answer to the warning letter,” said Dexcom in the submission.
It was unclear what specific problems the FDA identified in the facilities.
Dexcom produces devices that are known as continuous glucose monitors that can help users track their blood sugar and manage diabetes. The FDA warning letter does not limit Dexcom's ability to produce or drive out its products.
The company announced CNBC that the FDA “updated recurrently” since the agency carried out the inspections last year. Some of his observations have already been adequately addressed, and in the warning letter “specific areas for the further focus” have been detailed, said Dexcom.
“Dexcom is behind the standard of our products and undertakes to unravel all of the outstanding questions of the FDA as soon as possible,” said the company in an explanation.
Dexcom also appointed Renée Galá, Chief Operating Officer from Jazz Pharmaceuticals last week. Galá has been working in her current role since 2023 and previously worked as a Chief Financial Officer at Jazz.
She also has leadership roles in Grail and Theravance Biopharma and spent several years in the pharmaceutical Eli Lilly.
“Renées extensive experience with the management of world financial and global operations, including trade and F&E to advertise growth and create the shareholder value, is a superb fit on the journey of Dexcom,” said Kevin Sayer, CEO of Dexcom, in a publication.
From the intraday trade on Tuesday morning, Dexcom's shares have so far declined by about 9%.
Read the complete publication Here.
Feel free to send suggestions, suggestions, story ideas and data to Ashley at Ashley.capoot@nbcuni.com.
image credit : www.cnbc.com